stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) EBITDA
NewAmsterdam Pharma Company N.V.'s EBITDA for fiscal 2025 was −$225.5M, compared with −$176.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$233.2M. Over the past ten years it has ranged from −$225.5M (fiscal 2025) to −$127.7K (fiscal 2020) — the current reading is the lowest in ten years. NewAmsterdam Pharma Company N.V. ranks 529th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$225.5M | — |
| FY2024 | −$176.2M | — |
| FY2023 | −$182.9M | — |
| FY2022 | −$3.5M | — |
| FY2021 | −$1.4M | — |
| FY2020 | −$127.7K | — |
| FY2020 | −$127.7K | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$44.1M | — |
| Jun 2026 | −$64.8M | — |
| Mar 2026 | −$58.4M | — |
| Dec 2025 | −$65.9M | — |
| 21 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| MBX MBX Biosciences, Inc. compare | −$117.7M |
| XNCR Xencor, Inc. compare | −$209.4M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. | −$233.2M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$253.7M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement